Vaccine Activities Update
National Institute of Allergy and Infectious Diseases, National Institutes of Health

Claire Schuster, MPH
Division of Microbiology and Infectious Diseases
NIAID, NIH, DHHS

December 2015
Developing a Vaccine for Respiratory Syncytial Virus (RSV)

- RSV: A leading cause of pneumonia among infants and young children
- Currently no approved vaccine to prevent RSV infection
- Live intranasal vaccine candidate
  - Developed by NIAID, Johns Hopkins Bloomberg School of Public Health and MedImmune, LLC
- Phase 1 clinical trial:
  - Experimental vaccine appears to elicit stronger protective immune response than the previous lead vaccine candidate


Chickenpox Vaccine and Children with HIV

What is the most effective way to protect children with HIV from the chickenpox virus?

Children infected with HIV since birth benefit from two doses of the chickenpox vaccine
- Confers long-term protection in children on anti-HIV therapy

Study suggests that best approach is to give first dose at least 3 months after starting anti-HIV treatment

Ebola Vaccine Research

- NIAID supports development, preclinical and clinical testing of investigational Ebola vaccine regimens

- Johnson & Johnson (Crucell/Janssen) + Bavarian Nordic
  - Combined adenovirus/MVA platform
  - Designed to protect against strain responsible for 2014 outbreak

Credit: NIAID

NIH-Sponsored Clinical Trial of Chikungunya Vaccine Opens

This digitally-colorized transmission electron micrograph depicts numerous chikungunya virus particles. Credit: CDC
Precision Medicine Initiative

NIH Releases Funding Opportunities for Precision Medicine Initiative Programs
To create framework for proposed national research cohort